Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
Primary Industries
- Drugs
- Cancer
- Disease
- DNA
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 256489
IPSCIO Record ID: 74574
IPSCIO Record ID: 336357
For the TAL Patent Rights, Licensor grants the right to use the TAL nucleases engineered by Licensor pursuant to this Agreement to Develop Licensee license products until the filing of an IND for each Licensee Licensed Product, in the Field.
Also, for an Exclusive License, Licensor grants an exclusive ( even as to Licensor) license under the TAL Patent Rights, to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and Commercialize such Licensee Licensed Product in the Field in the Territory.
For the Right of Reference, Licensor grants a Right of Reference, to any data Controlled by Licensor that relates to the Licensed Licensor Intellectual Property, the Agreement CAR-Ts, the Licensee Licensed Products or preclinical studies with respect to the Licensee Licensed Products and that Licensee reasonably believes may be necessary or useful to the Development.
For the License to Licensor Improvements, Licensor grants a nonexclusive, worldwide, sublicensable, perpetual and irrevocable license under any Licensor Improvements that were solely or jointly invented by the employees, agents or independent contractors of Licensee to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and Commercialize any products and processes.
Agreement CAR-T means any CAR-T utilizing the Licensor Technology that is identified, created or developed Targeting a Licensee Target.
CAR means a chimeric antigen receptor expressed from an experimentally validated Licensor viral construct with specific molecular architecture and signaling domain sequences.
CAR-T means a population of T-cells with a unique set of experimentally validated biologic attributes expressing a CAR construct produced using Licensor Technology.
Patents include
TAL Effector-mediated DNA modification,
Modular DNA binding domains and methods of use, and
Method for treating materials with pulsed electric field, and other patents.
CAR-T platform technology provides a proprietary, allogeneic approach (utilizing engineered T-cells from a single donor for use in multiple patients) to developing CAR-T therapies that is distinct from other autologous approaches (engineering a patient’s own T-cells to target tumor cells).
The Field means human oncologic therapeutic, diagnostic, prophylactic and prognostic purposes.
The Parties are collaborating to discover and research novel CAR-Ts active against certain designated targets and to provide for Licensee to further research, develop, manufacture and commercialize such CAR-Ts and products containing such CAR-Ts.
